Coloradoans sought for study
DENVER, Jan. 24 /PRNewswire/ -- Regenerative Sciences, Inc., creator of the Regenexx(TM) procedure that uses a patient's own stem cells to regenerate bone and cartilage, has announced a new clinical study using its patent pending processes to treat tendon injuries.
The company is recruiting patients with moderate to severe tennis elbow, partial rotator cuff tears or Achilles tendon tears, and moderate to severe plantar fasciitis. This study has been sanctioned by an independent research review board and involves using the patient's own stem cells to repair and strengthen these tissues.
"We have evidence from large animal models that our stem cell procedure may help heal these chronic tendon problems without the need for surgery," said Chris Centeno, M.D., creator of Regenexx and an international expert and specialist in musculoskeletal, spinal and neurological injury.
To be considered for the Regenexx tendon study, please email Regenexx@rsihealth.net. All costs directly related to the study will be covered by the company.
The study involves harvesting the patient's own mesenchymal stem cells, growing them in a culture using the company's patent pending procedure, and then injecting these culture expanded cells into an area in need of repair.
Repair of the degenerated or injured area usually takes place in two to three months, and many patients feel better in one to three months.
About Regenerative Sciences
Founded in 2006, Regenerative Sciences is the Denver-based developer of Regenexx(TM), a breakthrough non-surgical option for people suffering from various orthopedic disorders. Regenexx is a patent-pending procedure that uses a person's own stem cells and blood growth factors to regenerate bone and cartilage.
The physicians at Regenerative Sciences are dedicated to providing the
option of non-surgical joint repair to their patients. Headquartered
|SOURCE Regenerative Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved